The effect of lacosamide on calcitonin gene-related peptide serum level in episodic migraine patients: a randomized, controlled trial

Shimaa Elgamal; Sherihan Rezk Ahmed; Mohamed M Nahas; Shimaa R Hendawy; Osama Elshafei; Mohamed G Zeinhom

doi:10.1007/s13760-024-02499-9

The effect of lacosamide on calcitonin gene-related peptide serum level in episodic migraine patients: a randomized, controlled trial

Acta Neurol Belg. 2024 Mar 19. doi: 10.1007/s13760-024-02499-9. Online ahead of print.

Authors

Shimaa Elgamal¹, Sherihan Rezk Ahmed², Mohamed M Nahas³, Shimaa R Hendawy³, Osama Elshafei⁴, Mohamed G Zeinhom⁵

Affiliations

¹ Neurology Department, Faculty of Medicine, Kafr El-Sheikh University, Elgeish Street, Kafr El-Sheikh, Egypt.
² Neurology Department, Faculty of Medicine, Kafr El-Sheikh University, Elgeish Street, Kafr El-Sheikh, Egypt. sherihanrezk2016@gmail.com.
³ Clinical Pathology Department, Faculty of Medicine, Mansoura University, Al Korneish Street, Mansoura, Egypt.
⁴ Neurology Department, Faculty of Medicine, Mansoura University, Al Korneish Street, Mansoura, Egypt.
⁵ Neurology Department, Faculty of Medicine, Kafr El-Sheikh University, Elgeish Street, Kafr El-Sheikh, Egypt. mohamed_gomaa@med.kfs.edu.eg.

PMID: 38502425
DOI: 10.1007/s13760-024-02499-9

Abstract

Background: Migraine affects 11-15% of people worldwide, and the calcitonin gene-related peptide (CGRP) is released during the migraine attack, producing pulsating pain of migraine. Also, lacosamide reacts with collapsin-response mediator protein 2, preventing its phosphorylation and leading to the inhibition of CGRP release in the trigeminal system.

Objective: The primary outcome was the difference in the serum level of CGRP-LI after three months of treatment with either lacosamide and ibuprofen or ibuprofen alone in episodic migraine patients. The secondary outcomes were assessing safety and efficacy of lacosamide in episodic migraine patients.

Methods: We conducted an open-label randomized controlled trial on episodic migraine patients aged 10-55 years diagnosed according to (ICHD-3) in Kafr El-Sheikh University Hospital, Egypt. We assessed serum levels of CGRP-LI before and three months after treatment in our two groups, the lacosamide, and the control groups. We also assessed the side effects of treatment in each group, the percentage of patients who achieved ≥ 50% reduction in the migraine monthly days (MMD) frequency and the percentage of patients who achieved pain freedom within 2 h in ≥ 4 of 5 attacks in each group.

Results: 200 episodic migraine patients completed the study. There was a statistically significantly higher reduction in the serum CGRP-LI level in the lacosamide group compared with the control group. In addition, lacosamide was well tolerated by patients. Also, the lacosamide group had statistically significant higher percentage of patients who achieved ≥ 50% reduction in the migraine monthly days (MMD) frequency and pain freedom within two hours in ≥ 4 of 5 attacks with P-values 0.002, 0.02 respectively.

Conclusion: The daily use of lacosamide 50 mg Bid for three months in episodic migraine patients was associated with a significant reduction in serum CGRP-LI, better clinical outcomes regarding frequency and duration of migraine attacks, and was well tolerated by patients. These results were derived from an open-label pilot study that needed to be thoroughly investigated by a large-scale, randomized, double-blinded, placebo-controlled study.

Trial registration: We registered our trial on ClinicalTrials.gov, named after "The Lacosamide's Effect on Calcitonin Gene-related Peptide in Migraine Patients," and with a clinical trial number (NCT05632133)-August 8, 2023.

Keywords: Calcitonin gene-related peptide; Egypt; Episodic migraine; Lacosamide.

Associated data

ClinicalTrials.gov/NCT05632133